An integrated genomic approach to the assessment and treatment of acute myeloid leukemia

Lucy A. Godley, John Cunningham, M. Eileen Dolan, R. Stephanie Huang, Sandeep Gurbuxani, Megan E. McNerney, Richard A. Larson, Hoyee Leong, Yves A Lussier, Kenan Onel, Olatoyosi Odenike, Wendy Stock, Kevin P. White, Michelle M. Le Beau

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Traditionally, new scientific advances have been applied quickly to the leukemias based on the ease with which relatively pure samples of malignant cells can be obtained. Currently, our arsenal of approaches used to characterize an individual's acute myeloid leukemia (AML) combines hematopathologic evaluation, flow cytometry, cytogenetic analysis, and molecular studies focused on a few key genes. The advent of high-throughput methods capable of full-genome evaluation presents new options for a revolutionary change in the way we diagnose, characterize, and treat AML. Next-generation DNA sequencing techniques allow full sequencing of a cancer genome or transcriptome, with the hope that this will be affordable for routine clinical care within the decade. Microarray-based testing will define gene and miRNA expression, DNA methylation patterns, chromosomal imbalances, and predisposition to disease and chemosensitivity. The vision for the future entails an integrated and automated approach to these analyses, bringing the possibility of formulating an individualized treatment plan within days of a patient's initial presentation. With these expectations comes the hope that such an approach will lead to decreased toxicities and prolonged survival for patients.

Original languageEnglish (US)
Pages (from-to)215-224
Number of pages10
JournalSeminars in Oncology
Volume38
Issue number2
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Genome
Cytogenetic Analysis
DNA Methylation
MicroRNAs
DNA Sequence Analysis
Transcriptome
Flow Cytometry
Leukemia
Gene Expression
Survival
Therapeutics
Genes
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Godley, L. A., Cunningham, J., Dolan, M. E., Huang, R. S., Gurbuxani, S., McNerney, M. E., ... Le Beau, M. M. (2011). An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Seminars in Oncology, 38(2), 215-224. https://doi.org/10.1053/j.seminoncol.2011.01.003

An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. / Godley, Lucy A.; Cunningham, John; Dolan, M. Eileen; Huang, R. Stephanie; Gurbuxani, Sandeep; McNerney, Megan E.; Larson, Richard A.; Leong, Hoyee; Lussier, Yves A; Onel, Kenan; Odenike, Olatoyosi; Stock, Wendy; White, Kevin P.; Le Beau, Michelle M.

In: Seminars in Oncology, Vol. 38, No. 2, 04.2011, p. 215-224.

Research output: Contribution to journalArticle

Godley, LA, Cunningham, J, Dolan, ME, Huang, RS, Gurbuxani, S, McNerney, ME, Larson, RA, Leong, H, Lussier, YA, Onel, K, Odenike, O, Stock, W, White, KP & Le Beau, MM 2011, 'An integrated genomic approach to the assessment and treatment of acute myeloid leukemia', Seminars in Oncology, vol. 38, no. 2, pp. 215-224. https://doi.org/10.1053/j.seminoncol.2011.01.003
Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME et al. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Seminars in Oncology. 2011 Apr;38(2):215-224. https://doi.org/10.1053/j.seminoncol.2011.01.003
Godley, Lucy A. ; Cunningham, John ; Dolan, M. Eileen ; Huang, R. Stephanie ; Gurbuxani, Sandeep ; McNerney, Megan E. ; Larson, Richard A. ; Leong, Hoyee ; Lussier, Yves A ; Onel, Kenan ; Odenike, Olatoyosi ; Stock, Wendy ; White, Kevin P. ; Le Beau, Michelle M. / An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. In: Seminars in Oncology. 2011 ; Vol. 38, No. 2. pp. 215-224.
@article{e6960f891a1d48c1bc25b9d978eaec38,
title = "An integrated genomic approach to the assessment and treatment of acute myeloid leukemia",
abstract = "Traditionally, new scientific advances have been applied quickly to the leukemias based on the ease with which relatively pure samples of malignant cells can be obtained. Currently, our arsenal of approaches used to characterize an individual's acute myeloid leukemia (AML) combines hematopathologic evaluation, flow cytometry, cytogenetic analysis, and molecular studies focused on a few key genes. The advent of high-throughput methods capable of full-genome evaluation presents new options for a revolutionary change in the way we diagnose, characterize, and treat AML. Next-generation DNA sequencing techniques allow full sequencing of a cancer genome or transcriptome, with the hope that this will be affordable for routine clinical care within the decade. Microarray-based testing will define gene and miRNA expression, DNA methylation patterns, chromosomal imbalances, and predisposition to disease and chemosensitivity. The vision for the future entails an integrated and automated approach to these analyses, bringing the possibility of formulating an individualized treatment plan within days of a patient's initial presentation. With these expectations comes the hope that such an approach will lead to decreased toxicities and prolonged survival for patients.",
author = "Godley, {Lucy A.} and John Cunningham and Dolan, {M. Eileen} and Huang, {R. Stephanie} and Sandeep Gurbuxani and McNerney, {Megan E.} and Larson, {Richard A.} and Hoyee Leong and Lussier, {Yves A} and Kenan Onel and Olatoyosi Odenike and Wendy Stock and White, {Kevin P.} and {Le Beau}, {Michelle M.}",
year = "2011",
month = "4",
doi = "10.1053/j.seminoncol.2011.01.003",
language = "English (US)",
volume = "38",
pages = "215--224",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - An integrated genomic approach to the assessment and treatment of acute myeloid leukemia

AU - Godley, Lucy A.

AU - Cunningham, John

AU - Dolan, M. Eileen

AU - Huang, R. Stephanie

AU - Gurbuxani, Sandeep

AU - McNerney, Megan E.

AU - Larson, Richard A.

AU - Leong, Hoyee

AU - Lussier, Yves A

AU - Onel, Kenan

AU - Odenike, Olatoyosi

AU - Stock, Wendy

AU - White, Kevin P.

AU - Le Beau, Michelle M.

PY - 2011/4

Y1 - 2011/4

N2 - Traditionally, new scientific advances have been applied quickly to the leukemias based on the ease with which relatively pure samples of malignant cells can be obtained. Currently, our arsenal of approaches used to characterize an individual's acute myeloid leukemia (AML) combines hematopathologic evaluation, flow cytometry, cytogenetic analysis, and molecular studies focused on a few key genes. The advent of high-throughput methods capable of full-genome evaluation presents new options for a revolutionary change in the way we diagnose, characterize, and treat AML. Next-generation DNA sequencing techniques allow full sequencing of a cancer genome or transcriptome, with the hope that this will be affordable for routine clinical care within the decade. Microarray-based testing will define gene and miRNA expression, DNA methylation patterns, chromosomal imbalances, and predisposition to disease and chemosensitivity. The vision for the future entails an integrated and automated approach to these analyses, bringing the possibility of formulating an individualized treatment plan within days of a patient's initial presentation. With these expectations comes the hope that such an approach will lead to decreased toxicities and prolonged survival for patients.

AB - Traditionally, new scientific advances have been applied quickly to the leukemias based on the ease with which relatively pure samples of malignant cells can be obtained. Currently, our arsenal of approaches used to characterize an individual's acute myeloid leukemia (AML) combines hematopathologic evaluation, flow cytometry, cytogenetic analysis, and molecular studies focused on a few key genes. The advent of high-throughput methods capable of full-genome evaluation presents new options for a revolutionary change in the way we diagnose, characterize, and treat AML. Next-generation DNA sequencing techniques allow full sequencing of a cancer genome or transcriptome, with the hope that this will be affordable for routine clinical care within the decade. Microarray-based testing will define gene and miRNA expression, DNA methylation patterns, chromosomal imbalances, and predisposition to disease and chemosensitivity. The vision for the future entails an integrated and automated approach to these analyses, bringing the possibility of formulating an individualized treatment plan within days of a patient's initial presentation. With these expectations comes the hope that such an approach will lead to decreased toxicities and prolonged survival for patients.

UR - http://www.scopus.com/inward/record.url?scp=79952938789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952938789&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2011.01.003

DO - 10.1053/j.seminoncol.2011.01.003

M3 - Article

VL - 38

SP - 215

EP - 224

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -